4.47

0.00% 0.00

After Hours: 4.55 0.08 +1.79%

Aptevo Therapeutics Inc (APVO)

Overview News Price History Financials Discussions Forecast Stock Split

Aptevo Therapeutics Inc stock is traded at $4.47, with a volume of 5,730. It is up +0.00% in the last 24 hours and down -5.30% over the past month. Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Previous Close:

$4.47

Open:

$4.67

24h Volume:

5,730

Relative Volume:

0.15

Market Cap:

$5.57M

Revenue:

$12.99M

Net Income/Loss:

$-27.83M

P/E Ratio:

-0.0219

EPS:

-203.7366

Net Cash Flow:

$-26.98M

1W Performance:

-1.76%

1M Performance:

-5.30%

6M Performance:

-43.77%

1Y Performance:

-91.83%

1-Day Range:

$4.47

$4.67

1-Week Range:

$4.16

$4.67

52-Week Range:

$3.80

$59.40

Aptevo Therapeutics Inc Stock (APVO) Company Profile

Name

Aptevo Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

206-838-0500

Address

2401 4TH AVE., SEATTLE, WA

Employee

Twitter

@aptevo

Next Earnings Date

2026-08-10

Latest SEC Filings

APVO's Discussions on Twitter

Compare APVO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APVO Aptevo Therapeutics Inc	4.47	5.53M	12.99M	-27.83M	-26.98M	-203.74
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-18	Initiated	Ladenburg Thalmann	Buy
Oct-05-17	Resumed	Piper Jaffray	Overweight

Aptevo Therapeutics Inc Stock (APVO) Latest News

Jul 01, 2026

Grant supports Aptevo’s immunotherapy APVO-451 for solid tumors - BioWorld News

Jul 01, 2026

Jun 30, 2026

Aptevo Therapeutics Secures Grant for APVO451 Development - TipRanks

Jun 30, 2026

Aptevo (NASDAQ: APVO) gets $1.5M CARE Fund grant to advance APVO451 - Stock Titan

Jun 30, 2026

Aptevo receives $1.5M grant for cancer therapy development - Investing.com

Jun 30, 2026

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - The Joplin Globe

Jun 30, 2026

Jun 28, 2026

Price to earnings forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView

Jun 27, 2026

Enterprise value to EBIT forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView

Jun 27, 2026

Price to earnings forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView

Jun 27, 2026

Jun 26, 2026

Aptevo Therapeutics, Inc. Actuals & Estimates (NASDAQ:APVO) - TradingView

Jun 26, 2026

Aptevo Therapeutics, Inc. Actuals & Estimates (MUN:AP82) - TradingView

Jun 26, 2026

Jun 25, 2026

Aptevo Therapeutics, Inc. Actuals & Estimates (FWB:AP82) - TradingView

Jun 25, 2026

AP82 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 23, 2026